

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, 5/10, C07K 14/715, 16/28, C12Q 1/68, G01N 33/50, A61K 38/17, 48/00		A1	(11) International Publication Number: WO 97/25424 (43) International Publication Date: 17 July 1997 (17.07.97)
(21) International Application Number: PCT/US97/00128 (22) International Filing Date: 2 January 1997 (02.01.97) (30) Priority Data: 08/582,825 4 January 1996 (04.01.96) US 08/774,414 31 December 1996 (31.12.96) US (60) Parent Application or Grant (63) Related by Continuation US 08/582,825 (CIP) Filed on 4 January 1996 (04.01.96)		(74) Agent: PESSIN, Karol, M.; Amgen Inc., Amgen Center, 1840 De Havilland Drive, Thousand Oaks, CA 91320-1789 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): AMGEN INC. [US/US]; Amgen Center, 1840 De Havilland Drive, Thousand Oaks, CA 91320-1789 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): CHANG, Ming-Shi [US/US]; 736 Calle Las Colinas, Newbury Park, CA 91320 (US). WELCHER, Andrew, Avery [US/US]; 786 Capitan Street, Thousand Oaks, CA 91320 (US). FLETCHER, Frederick, Addison [US/US]; 5031 Colony Drive, Camarillo, CA 93012 (US).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: OB PROTEIN RECEPTOR AND RELATED COMPOSITIONS AND METHODS

(57) Abstract

The present invention relates to a novel class of protein receptors, herein denominated "OB protein receptors" or "OB receptors", which are thought to selectively bind OB protein. As such, the novel OB protein receptor family is provided, as well as novel members of such family. Also provided are nucleic acids, vectors and host cells containing such nucleic acids, related antisense nucleic acids, molecules which selectively bind to the OB protein receptor, and related compositions of matter, such as OB receptor protein/OB protein complexes and pharmaceutical compositions. In other aspects, the present invention relates to methods of using the above compositions, such as therapeutic and/or diagnostic methods, and methods for preparing OB receptor ligands.

BEST AVAILABLE COPY